Acquisitions (Summary of Total Consideration) (Details) - In Process Research and Development [Member] $ in Millions |
May 25, 2018
USD ($)
|
|---|---|
| Acquired Finite-Lived Intangible Assets [Line Items] | |
| Cash paid for acquisition of Wilson Therapeutics outstanding shares | $ 749.3 |
| Transaction costs | 15.1 |
| Total consideration | 764.4 |
| Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Cash And Equivalents | 45.1 |
| Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles | 803.7 |
| Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Labor And Related Liabilities | (71.4) |
| Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Other | $ (13.0) |